Sheel Biotech Limited (NSE:SHEEL)
India
· Delayed Price · Currency is INR 46.90
+1.90 (4.22%)
At close: Apr 28, 2026
Sheel Biotech Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 1,123 | 1,018 | 922.82 | 801.16 | 707.36 | 630.28 |
| Revenue Growth (YoY) | - | 10.26% | 15.19% | 13.26% | 12.23% | - |
| Cost of Revenue | 716.94 | 657.16 | 576.22 | 541.43 | 478.27 | 427.3 |
| Gross Profit | 406.31 | 360.37 | 346.6 | 259.73 | 229.09 | 202.98 |
| Selling, General & Admin | 147.1 | 149.06 | 137.99 | 106.37 | 94.22 | 93.25 |
| Other Operating Expenses | 66.31 | 60.82 | 63.26 | 65.02 | 70.17 | 44.42 |
| Operating Expenses | 223.18 | 218.88 | 211.11 | 181.56 | 173.79 | 145.25 |
| Operating Income | 183.13 | 141.49 | 135.49 | 78.17 | 55.3 | 57.74 |
| Interest Expense | -17.97 | -14.46 | -11.5 | -11.17 | -9 | -7.73 |
| Interest & Investment Income | 0.78 | 0.78 | 0.76 | 0.57 | 3.01 | 0.84 |
| Currency Exchange Gain (Loss) | 0.47 | 0.47 | 1.06 | 0.17 | 0.29 | 0.04 |
| Other Non Operating Income (Expenses) | -2.06 | -3.05 | -3.29 | -4.04 | -1.08 | -3.9 |
| EBT Excluding Unusual Items | 164.35 | 125.23 | 122.52 | 63.7 | 48.53 | 46.98 |
| Gain (Loss) on Sale of Investments | 1.88 | 1.88 | - | - | - | - |
| Gain (Loss) on Sale of Assets | 1.13 | 1.13 | - | - | - | 1 |
| Other Unusual Items | - | - | - | - | - | -7.66 |
| Pretax Income | 167.35 | 128.23 | 122.52 | 63.7 | 48.53 | 40.32 |
| Income Tax Expense | 21.26 | 21.87 | 17.78 | 12.93 | -0.04 | 0 |
| Net Income | 146.09 | 106.36 | 104.75 | 50.77 | 48.57 | 40.31 |
| Net Income to Common | 146.09 | 106.36 | 104.75 | 50.77 | 48.57 | 40.31 |
| Net Income Growth | - | 1.54% | 106.34% | 4.52% | 20.48% | - |
| Shares Outstanding (Basic) | 15 | 15 | 15 | 15 | 15 | 4 |
| Shares Outstanding (Diluted) | 15 | 15 | 15 | 15 | 15 | 4 |
| Shares Change (YoY) | 0.56% | 1.71% | - | - | 250.00% | - |
| EPS (Basic) | 9.94 | 7.21 | 7.22 | 3.50 | 3.35 | 9.73 |
| EPS (Diluted) | 9.94 | 7.21 | 7.22 | 3.50 | 3.35 | 9.73 |
| EPS Growth | - | -0.14% | 106.29% | 4.51% | -65.58% | - |
| Free Cash Flow | 17.42 | 79.7 | -12.14 | 81.38 | 9.81 | - |
| Free Cash Flow Per Share | 1.19 | 5.40 | -0.84 | 5.61 | 0.68 | - |
| Dividend Per Share | - | - | 1.000 | 3.100 | 0.886 | - |
| Dividend Growth | - | - | -67.74% | 250.01% | - | - |
| Gross Margin | 36.17% | 35.42% | 37.56% | 32.42% | 32.39% | 32.20% |
| Operating Margin | 16.30% | 13.91% | 14.68% | 9.76% | 7.82% | 9.16% |
| Profit Margin | 13.01% | 10.45% | 11.35% | 6.34% | 6.87% | 6.40% |
| Free Cash Flow Margin | 1.55% | 7.83% | -1.31% | 10.16% | 1.39% | - |
| EBITDA | 192.91 | 150.49 | 145.36 | 88.34 | 64.7 | 65.31 |
| EBITDA Margin | 17.17% | 14.79% | 15.75% | 11.03% | 9.15% | 10.36% |
| D&A For EBITDA | 9.78 | 9 | 9.87 | 10.17 | 9.4 | 7.57 |
| EBIT | 183.13 | 141.49 | 135.49 | 78.17 | 55.3 | 57.74 |
| EBIT Margin | 16.30% | 13.91% | 14.68% | 9.76% | 7.82% | 9.16% |
| Effective Tax Rate | 12.70% | 17.06% | 14.51% | 20.30% | - | 0.01% |
| Revenue as Reported | 1,129 | 1,023 | 925.46 | 801.94 | 710.66 | 632.52 |
| Advertising Expenses | - | 4.44 | 4.11 | 1.49 | 1.75 | 3.87 |
Source: S&P Capital IQ. Standard template. Financial Sources.